Article

Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis

Division of Reproductive Biology Research, Department of Obsterics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
Biology of Reproduction (Impact Factor: 3.45). 11/2007; 77(4):681-7. DOI: 10.1095/biolreprod.107.061804
Source: PubMed

ABSTRACT Steroid receptors in the stromal cells of endometrium and its disease counterpart tissue endometriosis play critical physiologic roles. We found that mRNA and protein levels of estrogen receptor 2 (ESR2) were strikingly higher, whereas levels of estrogen receptor 1 (ESR1), total progesterone receptor (PGR), and progesterone receptor B (PGR B) were significantly lower in endometriotic versus endometrial stromal cells. Because ESR2 displayed the most striking levels of differential expression between endometriotic and endometrial cells, and the mechanisms for this difference are unknown, we tested the hypothesis that alteration in DNA methylation is a mechanism responsible for severely increased ESR2 mRNA levels in endometriotic cells. We identified a CpG island occupying the promoter region (-197/+359) of the ESR2 gene. Bisulfite sequencing of this region showed significantly higher methylation in primary endometrial cells (n = 8 subjects) versus endometriotic cells (n = 8 subjects). The demethylating agent 5-aza-2'-deoxycytidine significantly increased ESR2 mRNA levels in endometrial cells. Mechanistically, we employed serial deletion mutants of the ESR2 promoter fused to the luciferase reporter gene and transiently transfected into both endometriotic and endometrial cells. We demonstrated that the critical region (-197/+372) that confers promoter activity also bears the CpG island, and the activity of the ESR2 promoter was strongly inactivated by in vitro methylation. Taken together, methylation of a CpG island at the ESR2 promoter region is a primary mechanism responsible for differential expression of ESR2 in endometriosis and endometrium. These findings may be applied to a number of areas ranging from diagnosis to the treatment of endometriosis.

0 Followers
 · 
104 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The endometrium is the primary target organ for the 'female' sex steroid hormone estrogen, which exerts effects in the endometrium via two main classical estrogen receptor (ER) isoforms, ERα and ERβ. The main function of the endometrium, embryo implantation, appears unperturbed in ERβ knockout mice, which has led researchers to disregard other potentially important functional roles that ERβ may have in endometrium. This review focuses on ERβ in the human endometrium and its protective role from the undesired effects of ERα.
    Human Reproduction Update 10/2014; 21(2). DOI:10.1093/humupd/dmu053 · 8.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Study Question: What mechanism is involved in regulating the autophagy of endometrial stromal cells (ESCs), and does it participate in the pathogenesis of endometriosis? Summary Answer: CXCL12 down-regulates secretory phase ESC autophagy. What is Known Already: mTOR (mammalian target of rapamycin), the major negative regulator of autophagy, is abnormally increased in endometriotic lesions and is involved in the direct regulation of endometrial stromal cell (ESC) apoptosis. Study Design, Size, Duration: Autophagy was measured by transmission electron microscopy and immunofluorescence, and in vitro analysis was used to measure estrogen/CXCL12/CXCR4 signaling-mediated ESC autophagy. Participants/Materials, Setting, Methods: A total of 31 controls and 31 women with histologically confirmed endometriosis were included. We measured the autophagy level of normal and endometriosis-derived endometrium, and its relationship to the stage of endometriosis, as well as the potential molecular and signaling pathways that mediate the aberrant autophagy in endometriosis. Main Results and the Role of Chance: Compared to control secretory phase ESCs, a significant reduction of the autophagy grade ( as observed in TEM), punctuate LC3B staining (as observed in immunofluorescence assays), and autophagy-associated protein levels were exhibited in secretory phase eutopic ESCs (P<0.05) and ectopic ESCs (P<0.05) from women with endometriosis. In addition, the autophagy level was strong negatively correlated with the CXCL12 concentration in ESCs (R2= -0.9694). However, there was no significant difference in autophagy grade or CXCL12 concentration between stage I-II and stage III-IV endometriosis-derived ectopic ESCs (P>0.05). Based on a human autophagy PCR array, CXCL12 and CXCR4, which is the CXCL12 receptor, in ESCs were predicted to be molecules that mediate the abnormally lower autophagy in endometriosis. Accordingly, after estradiol (E2) treatment a marked increase in CXCL12 secretion (1.71-fold, P<0.01) and CXCR4 expression (5.07-fold, P<0.01) in secretory phase ESCs was observed together with decreases in autophagy grade (TEM), punctuate LC3B immunofluorescent staining and autophagy-associated protein levels (P<0.05). These changes could be reversed by progesterone (P4) (P<0.05). The suppression of autophagy induced by E2 and recombinant human CXCL12 protein could be abrogated by an anti-CXCR4 neutralizing antibody and by an NF-κB inhibitor (P<0.05), respectively. In addition, estrogen-stimulated CXCL12 secretion led to a low population of S phase cells (P<0.05), as well as a low level of apoptosis (P<0.05) in secretory phase ESCs. Limitations, Reasons for Caution: Further studies are needed to examine the mechanism of autophagy on ESC apoptosis. Wider implications of the Findings: Measures to increase in endometrial autophagy might be a valid, novel approach to reduce local E2-dependent growth of endometriotic tissue. Study Funding/Competing Interest(s): This study was supported by the National Natural Science Foundation of China (NSFC) (81471513, 81471548 and 81270677), the Training Program for Young Talents of Shanghai Health System XYQ2013104, the Program for Zhuoxue of Fudan University, and the Program for Creative Talents Education of Key Disciplines of Fudan University. None of the authors has any conflict of interest to declare.
    Human Reproduction 05/2015; DOI:10.1093/humrep/dev100 · 4.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endometriosis is a prevalent gynecological disorder in which endometrial tissue proliferates in extra-uterine sites, such as the peritoneal cavity, eventually giving rise to painful, invasive lesions. Dysregulated estradiol (E) signaling has been implicated in this condition. However, the molecular mechanisms that operate downstream of E in the ectopic endometrial tissue are unknown. To investigate these mechanisms, we used a mouse model of endometriosis. Endometrial tissue from donor mice was surgically transplanted on the peritoneal surface of immunocompetent syngeneic recipient mice, leading to establishment of cystic endometriosis-like lesions. Our studies revealed that treatment with E led to ∼3-fold increase in the lesion size within a week of transplantation. E also caused a concomitant stimulation in the expression of CCN1, a secreted cysteine-rich matricellular protein, in the lesions. Interestingly, CCN1 is highly expressed in human ectopic endometriotic lesions. To address its role in endometriosis, endometrial tissue from Ccn1-null donor mice was transplanted in wild-type recipient mice. The resulting ectopic lesions were reduced up to 75 in size compared to wild-type lesions due to diminished cell proliferation and cyst formation. Notably, loss of CCN1 also disrupted development of vascular networks in the ectopic lesions and reduced the expression of several angiogenic factors, such as VEGFA and VEGFC. These results suggest that CCN1, acting downstream of E, critically controls cell proliferation and neovascularization, which support the growth and survival of endometriotic tissue at ectopic sites. Blockade of CCN1 signaling during early stages of lesion establishment may provide a therapeutic avenue to control endometriosis.
    Molecular Endocrinology 10/2014; 28(12):me20141080. DOI:10.1210/me.2014-1080 · 4.20 Impact Factor